Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5250
-0.0222-4.06%
Pre-market: 0.53000.0050+0.95%08:22 EDT
Volume:2.59M
Turnover:1.39M
Market Cap:158.40M
PE:-1.86
High:0.5600
Open:0.5600
Low:0.5250
Close:0.5472
52wk High:3.18
52wk Low:0.4111
Shares:301.71M
Float Shares:239.00M
Volume Ratio:0.56
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2826
EPS(LYR):-0.4856
ROE:-292.47%
ROA:-41.15%
PB:8.08
PE(LYR):-1.08

Loading ...

Press Release: Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Dow Jones
·
May 13

Sangamo Therapeutics Delays Q1 2025 Earnings Call to Later Time on May 12

Reuters
·
May 13

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
May 10

Press Release: Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Dow Jones
·
May 07

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
May 05

US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Benzinga
·
Apr 04

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Benzinga
·
Apr 04

Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

Dow Jones
·
Apr 04

BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System

Reuters
·
Apr 04

Shares of Sangamo Therapeutics Rally on Licensing Deal With Eli Lilly

Dow Jones
·
Apr 04

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours

MT Newswires Live
·
Apr 04

Sangamo Therapeutics Enters Capsid License Agreement With Lilly

Dow Jones
·
Apr 04

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5

MT Newswires Live
·
Mar 19

Sangamo Therapeutics Price Target Maintained With a $2.00/Share by RBC Capital

Dow Jones
·
Mar 18

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

Benzinga
·
Mar 18

Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 18

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

Benzinga
·
Mar 18